tbuckley/cabot-search huggingface dataset:
1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Authors: G.K. Dy, B.C. Cho, J. Oliveira, M.D. Isla Casado, A. Blasco Cordellat, M. Zemanova, J. Roubec, L. Vila Martinez, L. Charbonnier, C. Soufflet, J. de Castro Carpeño
Journal: Annals of Oncology (2023)
1402P Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Authors: C. Audigier Valette, M. Pérol, N. Girard, L. Bosquet, L. De Gunten, G. Desamericq, L. Tzala, B. Allard, D. Debieuvre
Journal: Annals of Oncology (2023)
1323MO Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study
Authors: S. Hessey, W.K. Liu, O. Pich, A. Huebner, A. Bunkum, C. Richard, C. Puttick, C. Lombardelli, D. Moore, N. McGranahan, S. Zaccaria, C. Hiley, C. Swanton, M. Jamal-Hanjani
Journal: Annals of Oncology (2023)

Checkpoint inhibitors (CPIs) improve survival of patients with metastatic non-small cell lung cancer (NSCLC). However, in many patients the duration of response is limited, and some patients derive no benefit at all. Among key determinants of CPI response are genomic alterations that impair the anti-tumour immune response. In primary NSCLC these alterations are common. However, due to challenges collecting metastasis samples, the prevalence and distribution of these alterations across metastases within patients, and how this impacts response to CPI is not known. The PEACE autopsy study in tandem with the TRACERx study enables multi-region tumour sampling from diagnosis of NSCLC to death, allowing immune evasive capacity to be tracked across space and time. We performed exome sequencing on 84 primary tumour regions and 320 metastases from 21 patients recruited to these studies. Mutations and copy number alterations were called with our bioinformatic pipeline and used to infer tumour clones in each sample, their phylogenetic relationship and metastatic migration history. The neoantigen landscape and genomic alterations in genes involved in immune evasion (‘IE alterations’) were then characterised in each clone. We find IE alterations are frequent in metastases and emerge via distinct evolutionary paths. In a subset of patients, immune evasive primary tumour clones seed metastases, giving rise to metastases with poor T cell infiltrate that share IE alterations with the primary. In others, primary tumour seeding clones do not harbour IE alterations. Compared to patients with shared IE alterations, these patients’ metastases have higher T cell infiltrate and acquire more metastasis unique IE alterations after seeding. Measuring the radiological growth of individual metastases in 7 of these patients treated with CPIs in the DARWIN II trial, we observe homogenous progression of metastases in patients with shared IE alterations, while patients with metastasis unique IE alterations exhibit heterogeneous metastasis growth rates. When IE alterations occur in relation to metastatic seeding dictates the distribution of immune evasive capacity across metastases, which impacts metastasis growth during CPI therapy.
1330P Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Authors: C. Zhou, A. Xiong, J. Fang, X. Li, Q. Xie, Q. Yu, L. Han, Z. Ma, J. Shi, B. Wang, M. Ji, G. Yang, T. Xu, M. Xu, Q. Liu, N. Wang, X. Yan
Journal: Annals of Oncology (2023)
922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Authors: G.J. Hanna, J. Kaczmar, D.P. Zandberg, D.J. Wong, E. Yilmaz, E.J. Sherman, A. Hernando Calvo, A.G. Sacco, D. Bohr, R. Reiners, S. Bilic, R. Salazar, E. Gharakhani, C.H. Chung
Journal: Annals of Oncology (2023)
1255P Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Authors: M.A. Fonseca Magalhaes Filho, P.N. Aguiar Junior, B.L. Fabre, F. Marques, B. Gutierres, W. Nassib William Junior, A. Del Giglio
Journal: Annals of Oncology (2023)
1217P Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Authors: T. Crook, M. Agarwal, J. Wadhwa, N. Shrivastava, S. Apurwa, H. Darokar, R. Datar, D. Akolkar, S. Schuster, A. Gaya, V. Datta, D.S. Patil, A. Saha, S. Sahni, S. Limaye
Journal: Annals of Oncology (2023)
1229P Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Authors: S. Limaye, F. Massoudi, N. Rohatgi, D. Akolkar, R. Datar, T. Crook, S. Schuster, V. Datta, P. Shejwalkar, S. Patel, K. O'Neill, D.S. Patil, N. Syed
Journal: Annals of Oncology (2023)
793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Authors: A.M. Catana, P-A. Just, G. De Rauglaudre, N. Raban, A. Chevalier, G. Ferron, M-C. Kaminsky-Forrett, I.L. Ray-Coquard, S. Hamizi, P-F. Combe, S. Abadie Lacourtoisie, F. Joly Lobbedez, J. Meunier, C. Lebreton, J. Alexandre, P. Follana, J-P. Lotz, F. Del Piano, O. Colomban, B. You
Journal: Annals of Oncology (2023)
800P Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Authors: S. Howlett, A.M. Berner, K. Connolly, A. Orosco Ttamina, A. D'Angelo, G. Gullick, H. Abdallah, J. Wood, U. Mukherjee, M. Azhar, D. Lee, P. Mahalingam, L. Tookman, L.H. Cossar, R. Miller, M. Hall, S. Khalique
Journal: Annals of Oncology (2023)
1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Authors: D.A. Breadner, G. Liu, J. Rothenstein, S. Verma, I. Menjak, P.K. Cheema, R. Juergens, H. Mithoowani, P. Bains, Y. Wang, P. Wheatley-Price, M. Vincent
Journal: Annals of Oncology (2023)
1233P Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Authors: X. Yang, D-L. He, Z-G. Xiong, B. Yan, Q-L. Li, D. Guo, A. Huang, Z. Feng, P-X. Lu, R-Q. Fu, K-H. Xie, Y-Y. Liu, H. Chen, M-Y. Su, Q. He, Z. Su, R. Liu, Y. Zhong, J. Fan, J. Zhou
Journal: Annals of Oncology (2023)
1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Authors: F.C. Saalfeld, J. Möller, S. Michels, C. Grohe, M. Wiesweg, C. Schubart, J. Alt, F. Griesinger, D. Kauffmann-Guerrero, J. Kulhavy, T.R. Overbeck, N. Pelusi, G. Rohde, C. Wesseler, I. Vathiotis, R. Veluswamy, O.M. Illini, S.I. Rothschild, P. Christopoulos, M. Wermke
Journal: Annals of Oncology (2023)
1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
Authors: E. Carcereny, E. Felip, M. Majem, B. Doger de Spéville, T.D. Clay, I. Bondarenko, J. Peguero, M. Cobo Dols, M.D. Forster, G. Ursol, E. Kalinka, G.M. Garcia Ledo, L. Vila Martinez, W. Iams, M.G. Krebs, J. Kefas, K. Efthymiadis, S. Perera, C. Mueller, F. Triebel
Journal: Annals of Oncology (2023)
619P Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Authors: G. Ungerechts, D. Arnold, E. Goekkurt, A. Stein, J. Chater, U.M. Martens, H. Loghmani, M. Coffey, R. Trauger, T.C. Heineman
Journal: Annals of Oncology (2023)
1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
Authors: C.D. Rolfo, A.M. OBrate Grupp, C. Menzel, R. Bruns, D. Juraeva, C. Stroh, A. Johne, P.K. Paik
Journal: Annals of Oncology (2023)
856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis
Authors: D.P. Zandberg, D.A. Clump, B.R. Isett, R. Bao, H. Wang, L. Vujanovic, H. Li, J. Ohr, M. Fenton, H. Skinner, R. Seethala, None S. chiosea, B. Jonathan, J.E. Bauman, R. Ferris
Journal: Annals of Oncology (2023)

We previously reported numerically better efficacy with CRT with sequential (S) vs. concurrent (C) pembrolizumab (P). We now report updated results at 4-years and tumor-immune correlates. Patients (n=80) with HPV (-) LA HNSCC and intermediate risk HPV + oropharyngeal (> 10 pack years or T4 or N3) were randomized 1:1 to C (n=41) with P starting 1 week prior to CRT (cisplatin 40 mg/m2 weekly + RT 70 Gy in 35 fractions) vs. S (n=39) with P starting 2 weeks after CRT. P was 200mg q 3 weeks X 8 doses. Biopsies pre and on treatment (tx; during week 2 of CRT) were available in the first 33 (18C and 15S) patients (pts). Immune landscape was investigated using OPAL 7-color multispectral Vectra imaging, with cell segmentation and phenotyping in QuPath (cite). Cell densities (log % of total) for PD-L1+, CD8T (CD3+CD8+), and Treg (CD3+CD8-FOXP3+) cells were computed within tumor (PanCK+) or stroma (PanCK-) compartment. Pre/on tx differences by patient were compared using two-sided paired t-test at FDR corrected α = 0.05. Survival endpoints were summarized with the Kaplan-Meier method and compared between the two treatment arms with a Univariate Cox model. With a median follow up of 43 months, outcomes at 4-years in C vs. S are: Locoregional control (LRC) [64% vs. 96%, HR 0.12 95% CI (0.02, 0.94), p = 0.043], PFS [49% vs. 67%, HR 0.57 95% CI (0.26, 1.28), p=0.173], OS [ 71% vs. 83%, HR 0.51 95% CI (0.19, 1.37), p=0.181]. Analysis of paired pre/on-tx patient samples showed a significant increase in tumor PD-L1+ (p = 0.002) and stroma PD-L1+ cell densities in C (p = 0.048), with no change in tumor PD-L1+ cell density in S, after tx relative to baseline. No change was detected in CD8T infiltrates, Tregs, or CD8T to Treg ratio upon tx in C. Decreased stromal CD8T (p = 0.04) and Treg (p = 0.03) infiltrates were observed in S. Longer follow-up shows continued better outcomes in S, and a significant improvement in LRC. Our study uniquely compared pre and on tx paired patient samples by arm, with a significant decrease in stromal CD8 T cells and Tregs in S and increase in PD-L1+ cells in C, at two weeks into CRT. Further correlative analysis is ongoing.
1413P Patient-reported outcomes (PROs) from a phase 2 trial of telisotuzumab vedotin (Teliso-V) in c-Met–overexpressing, EGFR wild type, non-squamous non-small cell lung cancer (c-Met OE, EGFR WT, NSq NSCLC)
Authors: S. Lu, J. Bar, N. Girard, Q. Xu, R. Sen, C. Ratajczak, S. Ng, S. Xia, D.R. Camidge
Journal: Annals of Oncology (2023)
1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
Authors: J-J. Yang, Y. Zhang, L. Wu, J. Hu, Z-H. Wang, J-H. Chen, Y. Fan, G. Lin, Q-M. Wang, Y. Yao, J. Zhao, Y. Chen, J. Fang, Y. Song, W. Zhang, Y. Cheng, R-H. Guo, X-Y. Li, A-N. Li, Y-L. Wu
Journal: Annals of Oncology (2023)
795P Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Authors: J.F. Cueva Banuelos, C. Salvador Coloma, F. Galvez Montosa, J. Ferreiro Quintana, S. Cros Costa, S. González-Santiago, J.G. Cassinello, M. Romeo Marin, P. Reche, M.L. Soriano Tabares, M. Valero Arbizu, M.J. Rubio Perez, H.M. Oré Arce, L. Gaba Garcia, M.D.M. Gordon Santiago, C. Gomez Raposo, S. Hernando Polo, R. Marquez Vazquez, J. Fuentes Pradera, A. Gonzalez Martin
Journal: Annals of Oncology (2023)
1207O Beyond 100,000 genomes project: Whole genome sequencing for cancer patients within NHS Genomic Medicine Service
Authors: A.A. Sosinsky, S. Walker, J. Ambrose, R. Coleran, O. Yavorska, A. Hamblin, N. Murugaesu, P. Talley, S. Hing, J. Starczynski, S. Deans, S. Hill
Journal: Annals of Oncology (2023)
863P Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
Authors: D. Galizia, S. Minei, A. Abbona, M. Paccagnella, G. Piccinno, A. Polidori, L. De Zarlo, M. Albini, A. Rizzo, D. Campanella, G. Cappello, F. Enrico, S. Bondi, N. Segata, V. Gregorc, M.C. Merlano
Journal: Annals of Oncology (2023)
1403P Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Authors: M.L. Reale, F. Passiglia, M. Brambilla, G. Pasello, G. Minuti, A. Bulotta, P. Pizzutilo, C. Sini, J. Costa, E. Roca, E. Bria, S. Pilotto, C. Genova, G. Metro, F. Citarella, P. Bordi, A. Russo, R. Chiari, K. Andrikou, S. Novello
Journal: Annals of Oncology (2023)
1246P Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Authors: J. Blanco Heredia, B.H. Diplas, O.S.M. El Nahhas, P. Selenica, F. Pareja, D. Mandelker, B. Weigelt, N. Riaz, E. Rosen, A. Sfeir, J.S. Reis-Filho
Journal: Annals of Oncology (2023)
1400P Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Authors: M. Wislez, C. Mascaux, J. Cadranel, Q. Thomas, C. Ricordel, A. Swalduz, E. Pichon, R. Veillon, V. Gounant, G. Rousseau Bussac, A-C. Madroszyk Flandin, C. Daniel, M. Ravoire, A-C. Métivier, P. Fournel, P. Missy, F. Morin, F. Guisier, V. Westeel
Journal: Annals of Oncology (2023)
1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Authors: M. LaRose, M. Zhou, S. Lu, H. Wei, S.E. Bates, L. Schwartz, A.T. Fojo
Journal: Annals of Oncology (2023)
1317MO Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Authors: Y. Ma, H. Zhao, Y. Zhao, Y. Cheng, J. Cui, G. Liu, D. Xiong, J. Zhang, L. Xu, J. Yu, L. Men, E. Liang, D. Yang, L. Zhang, Y. Zhai
Journal: Annals of Oncology (2023)
1387P Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study
Authors: H. Sun, Y. Ge, J. Wu, Y. Sun, J. Zhang, Q. Cheng, D. Wang, X. Wang, J. Li, X. Fu, H. Sun, A. Gao
Journal: Annals of Oncology (2023)
1383P Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Authors: A. Kron, M. Scheffler, M. Wiesweg, H-D. Hummel, J. Kulhavy, S. Gattenlöhner, J. Kollmeier, C. Schubart, T. Gross, M. Demes, S. Keymel, M. Joosten, S. Merkelbach-Bruse, C. Wölwer, K. Oeser, M. Zehaczek, U. Jeratsch, J. Wolf
Journal: Annals of Oncology (2023)
1399P Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Authors: J. Reuss, N. Gandhi, P. Walker, J. Nieva, J.G. Bustamante Alvarez, J. Carlisle, A. Desai, A.M. VanderWalde, P.C. Ma, S.V. Liu
Journal: Annals of Oncology (2023)
1381P TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Authors: P. Christopoulos, S. Ekman, F. Guisier, C. Ho, M. Blasi, H. Brunnstrom, J. Cvetkovic, D. Kazdal, J.B. Kuon, F. Haglund de Flon, A. Stenzinger, S. Wong, A. Hatswell, T. McLean, S. Bergman, K. Orlowski, A.M. OBrate Grupp, H. Vioix, M. Thomas
Journal: Annals of Oncology (2023)
1223P Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Authors: A. Ranghiero, E. Guerini Rocco, A. Rappa, D. Varcica, S.V. Taormina, R. Adorisio, L. Marinucci, I. Betella, G. Aletti, N. Colombo, N. Fusco, None C. casadio, C. Di Tonno, M. Barberis
Journal: Annals of Oncology (2023)
1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Authors: K. Verkerk, T. van der Wel, L.J. Zeverijn, B.S. Geurts, I.A.C. Spiekman, G.F. de Wit, P. Roepman, A. Jansen, V. van der Noort, E.F. Smit, A. Hoeben, L. Hendriks, C.M.L. Van Herpen, B. Piet, G. Herder, S.M.S. Hashemi, H. Gelderblom, H.M.W. Verheul, E.E. Voest, J. De Langen
Journal: Annals of Oncology (2023)
1407P Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Authors: N. Girard, M. Pérol, D. Debieuvre, L. Bosquet, C. Veillard, M. Caillon, L. Tzala, G. Desamericq, C. Audigier Valette
Journal: Annals of Oncology (2023)
1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Authors: F.C. Althoff, J.A. Stratmann, P. Doebel, A.N. Hünerlitürkoglu, N. Frost, P. Christopoulos, C. Meyer zum Büschenfelde, J. Alt, M. Webendoerfer, S. Kaldune, G. Tritchkova, C.F. Waller, J. Braess, H-G. Kopp, C. Grohe, C. Schumann, F. Griesinger, J.B. Kuon, M. Sebastian, N. Reinmuth
Journal: Annals of Oncology (2023)
1385P Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
Authors: M.F. Chen, E. Rosen, C. Falcon, M. Repetto, S.R. Yang, J. Chang, M.G. Kris, N. Rekhtman, M. Donoghue, A. Drilon
Journal: Annals of Oncology (2023)
1241P Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Authors: K. He, G. Absenger, C. Pickering, C. Guerrier, C. Dhar, G. Xu, J. Hartness, R. Rice, F. Schwarz, D. Serie, D. Hommes, L. Brcic
Journal: Annals of Oncology (2023)
1332P Efficacy and safety of gefitinib plus bevacizumab versus gefitinib monotherapy in patients with EGFR L858R mutant non-small cell lung cancer (NSCLC): A randomized, open-controlled, single-center trial
Authors: J. Wang, X. Zhao, K. Xiong, C. Liu, X. Wu, H. Wang, H. Yu, S. Sun, Z. Hu, Y. Lin, Y. Zhang, B. Yu, Z. Wu
Journal: Annals of Oncology (2023)
874P Artificial intelligence (AI)-powered spatial tumor-infiltrating lymphocyte (TIL) analysis in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitor (ICI) treatment
Authors: M. Hong, C.G. Kim, M.H. Hong, Y.W. Koh, H.J. Hong, D. Kim, N.S. Sim, C.G. Lee, K.H. Kim, S. Kim, C. Oum, Y. Lim, S. Song, C-Y. Ock, S.O. Yoon, H.R. Kim
Journal: Annals of Oncology (2023)
1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)
Authors: J.K. Rotow, S.N. Waqar, K.P. Papadopoulos, J-Y. Hung, A.I. Spira, H. Gan, T. Yoshida, C-H.S. Kuo, B. Doger de Spéville, E. Felip, K. Yoh, G. Morrison-Thiele, R. Robinson, N. Rudraganguly, R. Saab, B.C. Cho
Journal: Annals of Oncology (2023)
1254P Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Authors: S. Ayyachamy, G. Srinivasan, A. Perumalla, G. Nandakumar, P. Priya Vijayakumaran, H. Kim, D. Jawahar, A. Faizal, S. Dev Merlin
Journal: Annals of Oncology (2023)
1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Authors: D. Debieuvre, P. Macouillard, X. Quantin, M. Berktas, N. Girard, C. Audigier Valette, T. Filleron, S. Musilli, L. Bosquet, M. Pérol
Journal: Annals of Oncology (2023)
778P Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Authors: C-H. Lai, C-Y. Lin, A-S. Chao, A. Chao, R-C. Wu, A. Yu, Y-C. Tang, C-H. Fu, R. Huang
Journal: Annals of Oncology (2023)
622P Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Authors: M. Reiser, J. Uhlig, L. Jacobasch, L. Mueller, A. Schuch, L. Serrer, R. de Buhr, H.U. Siebenbach, T. Göhler, J.K. Schröder, D. Semsek, A. Koehler, P. Stübs, K.M. Potthoff, N.W. Marschner
Journal: Annals of Oncology (2023)
1378P Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Authors: Y-K. Shi, Y. Zheng, J. Chen, X. Yu, J. Fang, Y. Liu, D. Huang, T. Liu, H. Shen, S. Luo, H. Yu, Y. Cao, X. Zhang
Journal: Annals of Oncology (2023)
1235P Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Authors: A. Helland, G.O. Hjortland, L. Fagereng, L. Bjorge, B. Gilje, M.G. Cameron, T. Donnem, A. Flobak, S. Fluge, O.T.D. Nguyen, B. Mannsåker, A. Stensvold, H.E.G. Russnes, E. Bjørgo, T.K.K. Guren, S. Smeland, K. Tasken
Journal: Annals of Oncology (2023)
1384P Phase II study of cabozantinib in patients with MET-altered lung cancers
Authors: G. Harada, F.C. Santini, R.W. Repetti, J. Chang, S.R. Yang, Y-T. Lin, K.A. Moses, C. Falcon, C.J. Wilhelm, M. Goldstein, A. Makhnin, M.S. Ginsberg, A.J. Plodkowski, M.G. Kris, A. Drilon
Journal: Annals of Oncology (2023)
1253P Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Authors: M. Trautmann, K. Falkenberg, L. Braun, A-C. Puller, S. Kirmse, L. Heinst, R. Berthold, I. Isfort, M. Abbas, E. Wardelmann, W. Hartmann
Journal: Annals of Oncology (2023)
1228P A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Authors: N. Rohatgi, R. Kurzrock, V. Datta, S. Murthy, D. Fonseca, S. Kodandapani, V. Kunteepuram, S. Apurwa, A. Adhav, R. Chougule, D. Reismann, R. Datar, T. Crook, G. Kaye, N. Plowman, R. Tippett, D.S. Patil, S. Limaye, S.J. Rajappa
Journal: Annals of Oncology (2023)
871P Detection of circulating tumor DNA in operable loco-regionally advanced HPV-negative head and neck squamous cell carcinoma
Authors: L. Beaussire, A. Berghian, E. Bohers, M. Viennot, J. Libraire, N. Bon Mardion, E. Meret, R. Obongo, N. Sarafan-vasseur, F. Di Fiore, F. Clatot
Journal: Annals of Oncology (2023)
1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Authors: L. Nogova, F. Malchers, A. Hillmer, I. Terjung, H. Scharpenseel, S. Merkelbach-Bruse, A. Scheel, J. Siemanowski, M. Scheffler, J. Frank, P. Heiden, H-D. Hummel, M. Wermke, C. Grohe, A. Kron, N. Reinmuth, F. Griesinger, R. Thomas, R. Büttner, J. Wolf
Journal: Annals of Oncology (2023)
1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Authors: H. Lena, J. Cadranel, N. Girard, J. Mazieres, H. Curcio, R. Gille, A-C. Madroszyk Flandin, J.B. Auliac, O. Bylicki, C. Rieux, S. Couraud, F. Barlesi, E. Pichon, A-C. Métivier, H. Almotlak, L. Pabst, C. Deldycke, B. Duchemann, L. De Gunten, X. Quantin
Journal: Annals of Oncology (2023)
1210MO Comparison of clinical and radiological features-based and radiomics features-based models for pulmonary nodule malignancy prediction on CT images
Authors: F. Zeng, B. Wang, M. Peng, J. Tao, X. Tu, H. Lu, X. Qiu, Y. Yang, Q. Zeng, J-B. Fan, Q. Liu
Journal: Annals of Oncology (2023)